Venkat jasti

Suven Life gets patents for anti-neuro degeneration molecule

These patents are valid through 2032 and 2034, respectively, the drug maker said in a filing to the BSE.

Suven begins clinical trial of anti-depressant

Suven Life said the global antidepressant market is valued over $20 billion.

Suven Life gets patent for neuro-degenerative molecule

With this new patent, Suven has a total of 26 patents from New Zealand. The new patent is valid through 2033, Suven Life Sciences said in a BSE filing.

Suven Life gets patent for anti-neuro degenerative drug

Suven Life said it has been granted "one product patent from the US corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases".

Suven Life gets patent for neuro-degenerative drug

Suven Life Science grabs a patent by Australia for a drug used in the treatment of neuro-degenerative diseases.

Suven Life gets patent for neuro-degenerative drug

With these new patents, Suven has a total of 23 patent from Europe and 12 from Israel.

Suven gets 2 patents for molecules targeting CNS disorder

Drug firm Suven Life Sciences has been granted two product patents, one each in India and Japan, for molecules to be developed for treatment of neuro-degenerative diseases.

Suven Life gets patent for neuro-degenerative drug

With these new patents, Suven has a total of 24 granted patent from Canada, 22 from Europe and 21 from Hong Kong.

The growth for the year will normalise around 20%: Venkat Jasti, Chairman & CEO, Suven Life Science

"Speciality chemicals has more or less reached the top. It has reached saturation level and the growth will be 3 per cent to 5 per cent over the year," said Jasti.